Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Atrophin 1 Monoclonal Antibody (C1), Invitrogen™

Mouse Monoclonal Antibody

Supplier:  Invitrogen™ MA543943

 View more versions of this product

Catalog No. PIMA543943


Only null left
Add to Cart
This item is not returnable. View return policy

Description

Description

Dentatorubral pallidoluysian atrophy (DRPLA) is a rare neurodegenerative disorder characterized by cerebellar ataxia, myoclonic epilepsy, choreoathetosis, and dementia. The disorder is related to the expansion from 7-35 copies to 49-93 copies of a trinucleotide repeat (CAG/CAA) within this gene. The encoded protein includes a serine repeat and a region of alternating acidic and basic amino acids, as well as the variable glutamine repeat. Alternative splicing results in two transcripts variants that encode the same protein.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Atrophin 1
Monoclonal
1 mg/mL
PBS with 50% glycerol and 0.05% ProClin 300
P54259
ATN1
Asp879-Leu1190 (Accession P54259), with N-terminal His Tag.
100 μL
Primary
Human
Antibody
IgG2b κ
Western Blot
C1
Unconjugated
ATN1
ATN1; Atr1; atrophin 1; Atrophin1; atrophin-1; B37; D12S755E; dentatorubral pallidoluysian atrophy; dentatorubral-pallidoluysian atrophy protein; Dentatorubral-pallidoluysian atrophy protein homolog; Drpla; HRS; NOD
Mouse
Protein A/G
RUO
1822
-20°C
Liquid
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.